Curative Irradiation Treatment of Hepatocellular Carcinoma

TAKE-HOME MESSAGE

• The authors of this phase II trial evaluated stereotactic body radiation therapy (SBRT) as an ablative treatment in 43 patients with inoperable hepatocellular carcinoma (HCC). The rate of local control of the irradiated HCC at 18 months was 98%, and the median overall survival was 3.5 years.

• The use of SBRT was associated with excellent local control rates and survival outcomes among patients with inoperable HCC. SBRT may be used as a bridge to transplantation or as definitive therapy.

International Journal of Radiation Oncology*Biology*Physics

Curative Irradiation Treatment of Hepatocellular Carcinoma: A Multicenter Phase 2 Trial

Int. J. Radiat. Oncol. Biol. Phys 2020 Jan 27;[EPub Ahead of Print], J Durand-Labrunie, AS Baumann, A Ayav, V Laurent, E Boleslawski, S Cattan, E Bogart, MC Le Deley, V Steen, T Lacornerie, D Peiffert, X Mirabel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.